Company: AZN
Filing Date: 2025-11-06
Form Type: 6-K
Source: 0001654954-25-012630
Chunk: 12

Company: ASTRAZENECA PLC
Filing Date: 2025-11-06
Form: 6-K
Chunk 12
---
583 |            79 |                                       1,181 |   150 |  4,993 |       16 |   13 |
| -Operating                       
 Margin                           |      24% |               |                                             |       |    33% |     +1pp | +1pp |
| Net finance expense              |     -349 |             - |                                           - |    44 |   -305 |       -7 |   -9 |
| Taxation                         |     -709 |           -19 |                                        -225 |   -49 | -1,002 |       33 |   30 |
| EPS                              |    $1.64 |         $0.03 |                                       $0.62 | $0.09 |  $2.38 |       14 |   12 |

Profit and Loss drivers

Gross profit

The stable Gross Margin (Reported and Core) in 9M 2025 was a result of:

- Positive effects from geographic mix

- Negative effects from product mix. The rising contribution of Product Sales with profit sharing arrangements ( Lynparza , Enhertu , Tezspire , Koselugo ) has a negative impact on Gross Margin because AstraZeneca records Product Sales in certain markets and pays away a share of the gross profits to its collaboration partners. The profit share paid to partners is recorded in AstraZeneca's Cost of sales line

- Pricing adjustments, for example to sales reimbursed by the Medicare Part D programme in the US, diluted the Gross Margin

Variations in Gross Margin performance between periods can continue to be expected due to product seasonality, foreign exchange fluctuations, and other effects.

R&D expense

The change in R&D expense (Reported and Core) in the period was impacted by:

- Positive data read-outs for high-value pipeline opportunities that have ungated late-stage trials

- Investment in platforms, new technology and capabilities to enhance R&D capabilities

- Addition of R&D projects following completion of previously announced business development activity

SG&A expense

- The change in SG&A expense (Reported and Core) in the period was driven primarily by market development activities for launches and to support continued growth in existing brands

Other operating income and expense

- Other operating income in 9M 2025 consisted primarily of royalties and an upfront fee on a divestment

Net finance expense

Core Net finance expense decreased 4% (4% at CER) in 9M 2025,